• Preventing Growth of Hemangioma Tumors in Newborns: A Prospective Randomized Clinical Study

Your baby may qualify for a RESEARCH STUDY comparing the safety and efficacy of no treatment with two treatments that may prevent the growth of very early infantile hemangiomas – pulsed-dye laser and topical treatment with timolol maleate 0.5% ophthalmic solution. Currently, the most common treatment for hemangiomas is watchful waiting. But, pulsed-dye laser is widely used in children and is approved by the FDA for treating hemangiomas. This procedure has a few minor side effects that are most often temporary. Timolol is used frequently for the treatment of childhood glaucoma with few side effects, and has been shown to be effective in treating cases of hemangiomas in infants. It is not yet an approved treatment for hemangiomas. An important question being tested in this study is whether these treatments can prevent hemangiomas from growing, when used very early after the birth of your child.
To qualify, your infant should:
• Be less than 4 months of age, male or female
• Have one or more superficial hemangiomas in the very early stage
• Have no severe heart, asthma or lung disease
• Not be on any other treatment for the hemangioma

Study requirements include:
• Photos, measurements, and treatment with either pulsed-dye laser or timolol or no treatment
• Up to 13 study visits, less than 1 hour each, over two years period
• Up to $385 in compensation for time and travel (parking sticker will also be provided)

For more information, please email:
Ttran2@partners.org or call 617-724-4937

More information can be found at:
Institution  –  MGH - Massachusetts General Hospital, Boston, MA; BWH - Brigham and Women's Hospital, Boston, MA; NWH, Newton, MA; North Shore Medical Center, Salem, MA; Beth Israel Deaconess, Boston, MA; Boston University Medical Center, Boston, MA; MIT, Cambridge, MA; Massachusetts General Hospital - East, Charlestown, MA; MGH Institute of Health Professions, Boston, MA
Principal Investigator  – Richard R Anderson, MD
Enrollment Information
For further information about enrolling a patient in this trial, contact the person below.
Name  – Thanh Nga T Tran, MD PhD
Email  – ttran2@partners.org
Phone  – 617-724-4937